OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 16:03 UTC. Every row links to its source record.

SDHA succinate dehydrogenase complex flavoprotein subunit A

ENSG00000073578 · protein coding · Open Targets profile

Flavoprotein (FP) subunit of succinate dehydrogenase (SDH) that is involved in complex II of the mitochondrial electron transport chain and is responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed:10746566, PubMed:24781757). SDH also oxidizes malate to the non-canonical enol form of oxaloacetate, enol- oxaloacetate (By similarity). Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerized into keto-oxaloacetate (By similarity). Can act as a tumor suppressor (PubMed:20484225). {ECO:0000250|UniProtKB:P31039, ECO:0000269|PubMed:10746566, ECO:0000269|PubMed:20484225, ECO:0000269|PubMed:24781757}.

In 8 of 15 cancers, the evidence for SDHA comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751pheochromocytoma/paraganglioma syndrome…pheochromocytoma/paraganglioma syndrome 5pheochromocytoma/paraganglioma syndrome 5: germline 0.88gastrointestinal stromal tumorgastrointestinal stromal tumorgastrointestinal stromal tumor: somatic 0.70gastrointestinal stromal tumor: germline 0.82hereditary pheochromocytoma-paraganglio…hereditary pheochromocytoma-paragangliomahereditary pheochromocytoma-paraganglioma: germline 0.73hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.94paragangliomaparagangliomaparaganglioma: somatic 0.46paraganglioma: germline 0.61rhabdomyosarcomarhabdomyosarcomarhabdomyosarcoma: germline 0.68kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61Carney-Stratakis syndromeCarney-Stratakis syndromeCarney-Stratakis syndrome: germline 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61pheochromocytomapheochromocytomapheochromocytoma: germline 0.56hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.45

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Structure with Ligand
Antibody
UniProt loc high conf
PROTAC
Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.6122199892997742 (upper bound 0.7787200212478638). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of SDHA's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of SDHA's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.